Why wait? Early combination therapy in diabetic kidney disease: lessons from CONFIDENCE

References

[1] Alicic RZ,Rooney MT,Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities Clin J Am Soc Nephrol 2017 12 2032 45 PMC5718284

[2] Jadoul M,Rossing P. The era of combination of nephroprotective agents in CKD is there Nephrol Dial Transplant 2025 40 i1 2 PMC11795657

[3] Agarwal R,Green JB,Heerspink HJL.et al. ; CONFIDENCE Investigators. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes N Engl J Med 2025 393 533 43

[4] Perkovic V,Jardine MJ,Neal B.et al. ; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy N Engl J Med 2019 380 2295 306

[5] Heerspink HJL,Stefánsson BV,Correa-Rotter R.et al. ; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease N Engl J Med 2020 383 1436 46

[6] Herrington WG,Staplin N,Wanner C.et al. ; The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease N Engl J Med 2023 388 117 27 PMC7614055

[7] Fadini GP,Longato E,Morieri ML,Del Prato S,Avogaro A,Solini A. DARWIN-Renal Study Investigators Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk Lancet Reg Health Eur 2024 38 100847 PMC10847023

[8] KDIGO 2026 clinical practice guideline for diabetes and chronic kidney disease (CKD) chapter 1, chapter 2, & chapter 4 update draft march 2026. Available from: https://kdigo.org/wp-content/uploads/2026/03/KDIGO-2026-Diabetes-and-CKD-Guideline-Update-Public-Review-Draft-March-2026.pdf. [Last accessed on 8 Sep 2026]

[9] Bakris GL,Agarwal R,Anker SD.et al. ; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes N Engl J Med 2020 383 2219 29

[10] Pitt B,Filippatos G,Agarwal R.et al. ; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes N Engl J Med 2021 385 2252 63

[11] Agarwal R,Filippatos G,Pitt B.et al. ; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis Eur Heart J 2022 43 474 84 PMC8830527

[12] Rossing P,Anker SD,Filippatos G.et al. ; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis Diabetes Care 2022 45 2991 8 PMC9862372

[13] Heerspink HJL,Collier WH,Chaudhari J.et al. A meta-analysis of albuminuria as a surrogate endpoint for kidney failure Nat Med 2026 32 281 7

[14] Agarwal R,Tu W,Farjat AE.et al. ; FIDELIO-DKD and FIGARO-DKD Investigators. Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes : a mediation analysis Ann Intern Med 2023 176 1606 16

[15] Wheeler DC,Pantalone KM,Guo L.et al. Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study Clin Kidney J 2025 18 sfaf305 PMC12598660

[16] Mottl A,Scott C,Green JB.et al. ; CONFIDENCE Trial Investigators. Baseline kidney function, albuminuria, and urine albumin-creatinine ratio reduction with finerenone, empagliflozin, or both: post hoc analyses of CONFIDENCE trial J Am Soc Nephrol 2026 37 764 76 PMC13065124

[17] Perkovic V,Tuttle KR,Rossing P.et al. ; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes N Engl J Med 2024 391 109 21

[18] Moedt E,Koshino A,Jongs N.et al. Association of urinary EGF with kidney outcomes and effects of sodium-glucose cotransporter 2 inhibition J Am Soc Nephrol 2026 Epub ahead of print